Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

• Autor(a) principal: Carvalho, D
• Data de Publicação: 2017
• Outros Autores: Russo, P, Bernardes, C, Saiote, J, Ramos, G, Mascarenhas, L, Borges, N, Ramos, J
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.17/2930
• topic: CHLC GAS; CHLC PAT CLIN; CHLC CIR; Crohn's Disease; Hodgkin's Disease/Chemically Induced; Infliximab; Lymphoproliferative Disorders; Tumor necrosis factor-α

INTRODUCTION: Lymphoproliferative disorders, particularly non-Hodgkin's and Hodgkin's lymphomas, are rare in patients with inflammatory bowel diseases. The use of thiopurines and infection by Epstein-Barr virus are well-known cofactors that can raise its prevalence. Other risk factors such as disease activity and biological treatment are the subject of discussion, without enough data in the literature to confirm a potential association. METHODS: We report a case of Hodgkin's lymphoma in a patient who had been treated with azathioprine and was on long-term monotherapy with infliximab. CONCLUSIONS: We stress the importance of recognizing the possible occurrence of a lymphoproliferative disorder in association with anti-tumor necrosis factor-α therapy.